Drug intelligence / Profile preview

KLA480

Development stage: Phase 1
Lead developer: Hunan Kelun Pharmaceutical
Modality: Small Molecules
Administration: Subcutaneous

Overview

KLA480 is a **chemical drug** in clinical development for the treatment of **Parkinson's disease**. It is being developed by Sichuan Kelun Pharmaceutical Research Institute (a subsidiary or division of Hunan Kelun Pharmaceutical Co., Ltd.). KLA480 is delivered via subcutaneous injection, and current clinical development is focused on evaluating its **safety, tolerability, and pharmacokinetics** in healthy participants. Its mechanism of action and molecular target have not been publicly disclosed. The drug is currently in **Phase 1 clinical trials**[1][3][7][9].

Brand names: KLA480KLA-480KLA 480
Other names: KLA480KLA-480KLA 480

Beyond the preview

Go deeper on KLA480.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLA480.

Explore the full profile